Browse press releases
The newest releases come first, each with its full text here and a link to its original. Try the filters to narrow them down.
- Green Choice Proteins Highlights Shift in Plant-Based NutritionBoca Raton, Florida Friday Oct 9, 2026 @ 3:00 PM Eastern — Green Choice Proteins, an Australian plant-based nutrition company preparing to expand into the United States, is highlighting an evolving approach to plant-based eating as consumers increasingly look beyond meat alternatives toward convenient, protein-rich foods and everyday nutrition products. Plant-based nutrition is no longer defined solely by consumers following vegan or vegetarian diets. Interest in incorporating more plant-derived ingredients into everyday meals has broadened the conversation to include protein content, ingredient transparency, flavor and convenience. For Green Choice Proteins, this evolution reflects the philosophy behind its Australian-made plant protein products, which are designed for consumers seeking practical ways to incorporate plant-based nutrition into their daily routines. "Plant-based nutrition doesn't have to be an all-or-nothing lifestyle choice," said Puneet Chawla, Founder of Green Choice Proteins. "We believe consumers should have access to high-quality plant protein products that fit naturally into their everyday lives, whether they're focused on fitness, general wellness or simply making more thoughtful food choices." Moving Beyond Traditional Plant-Based Categories As plant-based nutrition continues evolving, consumers have more options beyond products designed to replace meat or dairy. Plant proteins can also serve as convenient ingredients in smoothies, breakfast foods, baking and other everyday meals. Green Choice Proteins focuses on this broader approach, combining plant-derived protein with carefully selected ingredients and flavors designed to make everyday nutrition both convenient and enjoyable. The company's formulations feature Australian-grown pea and faba proteins, omega-3 from linseed and no artificial colours, flavours or fillers. Three Flavors Designed for Everyday Nutrition Green Choice Proteins' initial U.S. product lineup includes three plant-based protein powders: Chocolate Flavored Protein Powder - Plant-Based Protein 35.3g plant protein per serving Made with Australian-grown pea and faba Features pure cocoa powder and coconut milk powder Contains omega-3 from linseed No artificial colours, flavours or fillers Vanilla Flavored Protein Powder - Plant Based Protein 34.9g plant protein per serving Designed for smoothies, oats, baking and everyday nutrition routines Made using Australian-grown plant proteins Includes omega-3 from linseed Clean vanilla flavor profile without artificial additives Salted Caramel Flavored Protein Powder - Plant Based Protein 34.9g plant protein per serving Combines caramel sweetness with balanced salted notes Made using Australian-grown pea and faba Includes omega-3 from linseed No artificial colours, flavours or fillers "Taste and convenience are just as important as the nutritional profile," added Chawla. "Our goal is to create products that people genuinely enjoy incorporating into their routines. We want plant-based nutrition to feel accessible and practical, not complicated or restrictive." Australian-Made Nutrition With a Focus on Transparency Manufactured in Victoria, Australia, Green Choice Proteins emphasizes ingredient transparency, responsible sourcing and clean-label formulations. The family-owned company uses Australian-grown pulses as a foundation for its products while incorporating other thoughtfully selected ingredients to create its plant protein formulations. Green Choice Proteins believes the growing interest in everyday plant-based nutrition creates opportunities for brands that can combine quality ingredients with enjoyable flavors and convenient formats. Building a Presence in the United States The company's focus on everyday plant nutrition comes as Green Choice Proteins continues its U.S. expansion strategy. Following its participation in September's ECRM Vitamin, Weight Management & Sports Nutrition Session in Palm Beach Gardens, Florida, the company is preparing to introduce its products to American consumers through OneLavi and Amazon. The upcoming launches represent the initial stages of Green Choice Proteins' broader strategy to establish its Australian-made plant nutrition products in the United States. For more information, visit Green Choice Proteins. About Green Choice Proteins Based in Victoria, Australia, Green Choice Proteins is a family-owned plant-based nutrition company focused on delivering clean, functional daily nutrition for modern lifestyles. Using plant proteins derived from Australian-grown crops and manufacturing its products in Victoria, the company combines high-quality plant protein with thoughtfully selected functional ingredients to support everyday wellness, performance, and recovery. Built on a philosophy of transparency, sustainability, and formulation integrity, Green Choice Proteins creates clean-label nutrition products with no artificial colours, flavours, or fillers, helping consumers simplify their wellness routines with trusted, Australian-made plant-based nutrition. Follow Green Choice Proteins on Instagram and Facebook.
- Advancing Access to Lung Cancer Care Through Artificial Intelligence InnovationAdvancing Access to Lung Cancer Care Through Artificial Intelligence Innovation Tue, 10/13/2026 - 08:00 Body Originally published on preventcancer.org This post has been sponsored by Bristol Myers Squibb as part of its sponsorship of the 2026 Prevent Cancer Gala. Can AI help close care gaps in lung cancer? Lung cancer remains the leading cause of cancer death in the United States, with the American Cancer Society projecting about 229,000 new diagnoses and 125,000 deaths in 2026 alone. Behind those numbers lies another part of the story: Medically underserved communities, including many rural areas, experience higher mortality rates for lung cancer and are also less likely to undergo routine screening or biomarker testing. At Bristol Myers Squibb (BMS), we believe artificial intelligence (AI) can help identify and quantify these health care gaps, accelerate individual diagnosis, detect disparities in treatment pathways, predict risk of outcomes and proactively target interventions. Two ongoing collaborations help demonstrate this approach. Catching cancer earlier BMS shares the Prevent Cancer Foundation’s goal to increase awareness about the importance of lung cancer screening to enable earlier detection and better outcomes. However, lung cancer nodules can be small and easily overlooked, and they are sometimes found by chance on imaging done for unrelated reasons. Even when a nodule is spotted, more than half of these patients don’t receive proper follow-up care and may never actually see a specialist. These challenges present an opportunity for improvement that BMS is tackling through our collaboration with Microsoft. Using AI algorithms that are cleared by the U.S. Food and Drug Administration (FDA), and deployed through Microsoft’s extensive Precision Imaging Network, will help radiologists analyze X-ray and CT images to flag hard-to-detect nodules. Then, workflow tracking tools will help ensure patients flagged with nodules are connected to care rather than fall through the cracks. This multi-year collaboration is currently in its first phase, recruiting pilot sites such as rural hospitals and community clinics. Supporting better treatment decisions after diagnosis A second opportunity begins after diagnosis. For patients with advanced non-small cell lung cancer (the most common form of lung cancer), selecting the most effective therapy depends on biomarker testing. These lab analyses identify specific genetic mutations driving a patient’s cancer. But biomarker testing doesn’t always happen as guidelines recommend, in part because lab and electronic health record systems are often disconnected. Through our collaboration with Tempus AI, BMS implemented the AI-enabled Tempus Next Pathways program across 13 community-based health systems to build a near real-time view of the patient journey, finding out where and why patients were not receiving the right care according to guidelines. The results were compelling. By providing these insights to clinical teams, guideline-directed biomarker testing rates rose from 73% to 84% across participating sites. The program also helped explain the reasons behind that gap, such as clinical factors like disease progression or transitions to hospice care, or logistical issues like patients relocating out of their previous health system. This information provided better tools to design targeted interventions. Two projects, one purpose Together, these two projects present a picture of what AI-enabled, data-driven and access-focused cancer care can look like: identifying cancer earlier through smarter imaging workflows and enabling evidence-based treatment. For BMS, that combination reflects a broader commitment, one shared with organizations like the Prevent Cancer Foundation, to help innovation in cancer care reach every community. Learn more about Advancing population health – Bristol Myers Squibb Canonical URL https://preventcancer.org/article/advancing-access-to-lung-cancer-care-through-… Featured Image Type of Content Article
- Tractor Beverage CompanyTractor Named to the 2026 Fortune Best Workplaces in Manufacturing & Production™ ListFarmer-founded, employee-owned beverage company ranks No. 34 among small and medium workplaces Tractor Beverage Company has been named to the 2026 Fortune Best Workplaces in Manufacturing & Production™ list, ranking No. 34 in the small and medium company category. Produced by Great Place To Work®, the list recognizes companies based on employees' feedback about their workplace experience. Tractor's
- Black Rock Coffee Bar Continues Austin-Area Growth with New Killeen LocationGrand Opening on October 13 Marks 13th Location in Austin Metro
- Wynn Resorts (Macau)Wynn Officially Unveils the Highly Acclaimed 2027 Wynn Signature Chinese Wine Awards in NovemberIn a first, Beijing will host the Judging Week, where the competition's international panel of wine experts explore China's rich culture and wine terroir — "Wynn Signature" – the exclusive lifestyle brand at Wynn – will unveil the full-year calendar and...
- NWB Finland Oy to Expands U.S. Retail Presence With AINA Natural Water Coming Soon to AmazonBoca Raton, Florida Friday Oct 9, 2026 @ 4:00 AM Eastern — NWB Finland Oy is continuing its planned U.S. rollout of AINA Natural Water, announcing that the Finnish premium water brand is coming soon to Amazon. The upcoming Amazon availability represents another step in NWB Finland Oy’s strategy to introduce AINA Natural Water to U.S. consumers. The company previously announced that AINA would become available through OneLavi.com, marking the first opportunity for U.S. consumers to purchase the brand. “Expanding to Amazon is an important next step for AINA in the United States,” said Marita Weiman, Quality Assurance Manager at NWB Finland Oy. “We want to make it easy for consumers to discover and purchase AINA while introducing them to what makes Northern Finnish water and our packaging approach different.” AINA Natural Water originates in the Pudasjärvi region of Northern Finland, where groundwater is naturally filtered through layers of soil, sand and rock before being mechanically filtered and packaged. The water contains approximately 32 mg/L of Total Dissolved Solids (TDS). Its naturally low mineral content contributes to a soft, neutral taste and clean finish with no aftertaste. Premium Water Designed for Everyday Living NWB Finland Oy has built AINA around the idea that premium water should be practical enough to become part of everyday life. Instead of focusing on individual plastic bottles, AINA is offered in larger 5-liter and 10-liter bag-in-box formats designed for convenient use at home, at work and in other everyday settings. The sustainability-focused packaging uses substantially less plastic than comparable volumes packaged in traditional individual plastic bottles. The approach combines three elements NWB Finland Oy believes can differentiate AINA in the U.S. market: Northern Finland source Naturally low mineral profile Sustainability-Focused Packaging AINA’s upcoming expansion to Amazon follows a series of steps by NWB Finland Oy to establish the brand in the United States. The company recently participated in the 2026 ECRM Vitamin, Weight Management & Sports Nutrition Session in Palm Beach Gardens, Florida, where AINA and its bag-in-box format were introduced to U.S. retail buyers. “We are building AINA’s U.S. presence step by step,” Weiman said. “Amazon will significantly broaden the opportunity for consumers across the country to experience AINA Natural Water.” The AINA Difference Northern Finland Source - Originates in the Pudasjärvi region of Northern Finland, an area known for its forests, natural landscapes, and groundwater resources. Naturally Filtered - Groundwater is naturally filtered through layers of soil, sand, and rock before being mechanically filtered and packaged. Measured Purity - Contains approximately 32 mg/L of Total Dissolved Solids (TDS), contributing to a soft, clean taste profile. Clean Taste Profile - Naturally low mineral content helps provide a balanced drinking experience with no aftertaste. Naturally Low in Sodium - Contains only small amounts of sodium and dissolved minerals. Sustainability-Focused Packaging - Bag-in-box packaging uses substantially less plastic than traditional bottled-water formats. Additional details about Amazon availability will be announced when AINA Natural Water becomes available for purchase. For more information about AINA Natural Water, visit AINA Natural Water. To learn more about NWB Finland Oy, visit NWB Finland Oy. About NWB Finland Oy NWB Finland Oy is a Finland-based company focused on sustainable beverage packaging and natural water solutions. Headquartered in Pudasjärvi, Finland, the company was founded with a mission to develop environmentally responsible alternatives to traditional beverage packaging while delivering premium-quality products to consumers around the world. Its flagship brand, AINA Natural Water, features naturally filtered groundwater sourced from Northern Finland, a region known for its pristine natural environment and abundant groundwater resources. The water is packaged in innovative bag-in-box formats designed to reduce plastic consumption while providing a convenient solution for households, businesses, hospitality venues, and events. NWB Finland Oy's long-term vision is to make Northern Finland's natural groundwater available to consumers globally while continuing to invest in sustainable packaging solutions that support both consumer needs and environmental responsibility.
- 94% of Indian consumers are interested in trying cultivated meat, reveals GFI India’s consumer perception studyGFI India study finds strong consumer curiosity and acceptance for cultivated meat, but affordability, accessibility and trust will be critical to driving adoption. A new study by the Good Food Institute India (GFI India) finds that 94% of consumers express an intention to try cultivated meat, signalling strong consumer curiosity and openness towards a new […]
- Two Former Moderna Cancer Vaccine Scientists Join Everest Medicines, Accelerating Global Development of Its mRNA PlatformHong Kong, Oct 9, 2026 - Everest Medicines (1952.HK) announced the appointments of Lakshmi Srinivasan, PhD, as Senior Vice President, Head of Translational Medicine, and Brandon Coder, PhD, as Vice President, Translational Sciences & Discovery. Both executives are seasoned scientists in mRNA cancer vaccines, with deep experience spanning early discovery through clinical development and leadership roles in oncology vaccine research at Moderna and other leading biopharmaceutical companies. The appointments further strengthen the Company’s global R&D capabilities in mRNA therapeutics, and support the continued advancement of its proprietary mRNA platform and pipeline. At Everest, they will drive clinical development of the Company’s mRNA programs and expand Everest’s presence in the United States, in line with the Company’s global mRNA R&D strategy, while working closely with the China R&D team. The two scientists previously held leadership roles at Moderna, where they contributed to its mRNA cancer vaccine programs, including mRNA-4157/V940. Their experience spanning early-stage research through clinical development will support the advancement of Everest's proprietary mRNA platform and global clinical development programs. In August 2026, Moderna and Merck announced that mRNA-4157/V940 in combination with Keytruda met the primary endpoint of recurrence-free survival (RFS) and the key secondary endpoint of distant metastasis-free survival (DMFS) in the Phase 3 INTerpath-001 study. The results represent the first positive Phase 3 readout for an individualized neoantigen therapy (INT) and for an mRNA-based cancer therapy. “We are very pleased to welcome Dr. Srinivasan and Dr. Coder to Everest Medicines as we continue to strengthen our global mRNA R&D capabilities,” said Mr. Yifang Wu, Chairman of the Board of Everest Medicines. “Their deep experience in cancer vaccine research, translational medicine, and clinical development will be highly valuable as we advance our proprietary mRNA platform and broader pipeline. Their appointments reflect our continued commitment to investing in world-class talent and advancing our global mRNA strategy.” Dr. Srinivasan is a seasoned immunologist with 20 years of experience advancing innovative immuno-oncology therapeutics from discovery through clinical development. Her expertise spans cancer vaccines, mRNA-LNP technologies, T-cell therapies, and translational development from preclinical research through clinical proof of concept. Prior to joining Everest Medicines, Dr. Srinivasan served as Executive Director and Head of Oncology Translational Medicine at Moderna Therapeutics from 2023 to 2025. She previously held leadership roles at Repertoire Immune Medicines, Neon Therapeutics, which was later acquired by BioNTech, and Sanofi Oncology. Dr. Srinivasan has played a key role in the clinical translation of personalized neoantigen vaccines and has authored multiple high-profile publications in the field. She served as corresponding author on Phase 1b studies of NEO-PV-01 published in Cell (2020) and Cancer Cell (2022), and co-authored publications on Moderna’s intismeran autogene (mRNA-4157/V940), including the Phase 1 KEYNOTE-603 study published in Cancer Discovery (2024) and the three-year follow-up of the randomized Phase 2b KEYNOTE-942 study published in JCO Oncology Advances (2026). Dr. Coder brings more than 11 years of industry experience advancing T cell immunotherapies from discovery through investigational new drug (IND) submissions and early clinical proof of concept, with expertise in cancer vaccines, mRNA/LNP platform technology, and in vivo CAR therapies. Prior to joining Everest Medicines, Dr. Coder held scientific roles at Moderna from 2019 to 2025, most recently as Associate Scientific Director of Cancer Vaccine Research. He served as research and global pharmacology lead for intismeran autogene (mRNA-4157/V940), which reported positive results from the Phase 3 INTerpath-001 study in August 2026, becoming the first personalized neoantigen therapy and mRNA cancer therapy to achieve success in a Phase 3 clinical study. Dr. Coder also co-invented and led development of the shared-antigen discovery and vaccine design framework for mRNA-4359 and mRNA-4106. He contributed to nine IND submissions as a co-inventor, research lead, or core contributor, and co-authored the Phase 1 KEYNOTE-603 study of mRNA-4157/V940 published in Cancer Discovery (2024). Prior to joining Moderna, Dr. Coder served as Associate Director of Immuno-Oncology Research at Advaxis Immunotherapies, where he developed personalized and off-the-shelf cancer vaccines. Leveraging its proprietary AI+mRNA platform, Everest Medicines is advancing multiple mRNA oncology therapeutic vaccine and in vivo CAR-T programs for oncology and autoimmune diseases. EVM16, a personalized mRNA therapeutic cancer vaccine, has completed its first-in-human clinical data readout, demonstrating a favorable safety and tolerability profile, robust immunogenicity and promising preliminary efficacy. Selected data were presented at the 2026 American Association for Cancer Research (AACR) Annual Meeting. Following the Phase 1a study, EVM16 plans to initiate an investigator-initiated trial (IIT) Phase 1b study in Q4 2026 and launch new indication expansion cohorts for efficacy exploration. The company plans to submit an IND application to the U.S. Food and Drug Administration (FDA) in the first half of 2027. EVM14, an off-the-shelf tumor-associated antigen (TAA) mRNA cancer vaccine, received IND clearance from the U.S. FDA and IND approval from China’s National Medical Products Administration (NMPA) in 2025. The Phase 1 monotherapy dose-escalation study is expected to be completed in Q1 2027.EVM18, an in vivo CAR-T therapy, has initiated an IIT study in autoimmune diseases, with global IND filing underway. EVM15, an off-the-shelf immunomodulatory (IM) cancer vaccine, achieved clinical proof of concept in preclinical studies in 2025, with a clinical candidate subsequently selected. The Company plans to advance preparations for the Investigational New Drug (IND) application for EVM15 in 2026.
- Two Former Moderna Cancer Vaccine Scientists Join Everest Medicines, Accelerating Global Development of Its mRNA PlatformHong Kong, Oct 9, 2026 - Everest Medicines (1952.HK) announced the appointments of Lakshmi Srinivasan, PhD, as Senior Vice President, Head of Translational Medicine, and Brandon Coder, PhD, as Vice President, Translational Sciences & Discovery. Both executives are seasoned scientists in mRNA cancer vaccines, with deep experience spanning early discovery through clinical development and leadership roles in oncology vaccine research at Moderna and other leading biopharmaceutical companies. The appointments further strengthen the Company’s global R&D capabilities in mRNA therapeutics, and support the continued advancement of its proprietary mRNA platform and pipeline. At Everest, they will drive clinical development of the Company’s mRNA programs and expand Everest’s presence in the United States, in line with the Company’s global mRNA R&D strategy, while working closely with the China R&D team. The two scientists previously held leadership roles at Moderna, where they contributed to its mRNA cancer vaccine programs, including mRNA-4157/V940. Their experience spanning early-stage research through clinical development will support the advancement of Everest's proprietary mRNA platform and global clinical development programs. In August 2026, Moderna and Merck announced that mRNA-4157/V940 in combination with Keytruda met the primary endpoint of recurrence-free survival (RFS) and the key secondary endpoint of distant metastasis-free survival (DMFS) in the Phase 3 INTerpath-001 study. The results represent the first positive Phase 3 readout for an individualized neoantigen therapy (INT) and for an mRNA-based cancer therapy. “We are very pleased to welcome Dr. Srinivasan and Dr. Coder to Everest Medicines as we continue to strengthen our global mRNA R&D capabilities,” said Mr. Yifang Wu, Chairman of the Board of Everest Medicines. “Their deep experience in cancer vaccine research, translational medicine, and clinical development will be highly valuable as we advance our proprietary mRNA platform and broader pipeline. Their appointments reflect our continued commitment to investing in world-class talent and advancing our global mRNA strategy.” Dr. Srinivasan is a seasoned immunologist with 20 years of experience advancing innovative immuno-oncology therapeutics from discovery through clinical development. Her expertise spans cancer vaccines, mRNA-LNP technologies, T-cell therapies, and translational development from preclinical research through clinical proof of concept. Prior to joining Everest Medicines, Dr. Srinivasan served as Executive Director and Head of Oncology Translational Medicine at Moderna Therapeutics from 2023 to 2025. She previously held leadership roles at Repertoire Immune Medicines, Neon Therapeutics, which was later acquired by BioNTech, and Sanofi Oncology. Dr. Srinivasan has played a key role in the clinical translation of personalized neoantigen vaccines and has authored multiple high-profile publications in the field. She served as corresponding author on Phase 1b studies of NEO-PV-01 published in Cell (2020) and Cancer Cell (2022), and co-authored publications on Moderna’s intismeran autogene (mRNA-4157/V940), including the Phase 1 KEYNOTE-603 study published in Cancer Discovery (2024) and the three-year follow-up of the randomized Phase 2b KEYNOTE-942 study published in JCO Oncology Advances (2026). Dr. Coder brings more than 11 years of industry experience advancing T cell immunotherapies from discovery through investigational new drug (IND) submissions and early clinical proof of concept, with expertise in cancer vaccines, mRNA/LNP platform technology, and in vivo CAR therapies. Prior to joining Everest Medicines, Dr. Coder held scientific roles at Moderna from 2019 to 2025, most recently as Associate Scientific Director of Cancer Vaccine Research. He served as research and global pharmacology lead for intismeran autogene (mRNA-4157/V940), which reported positive results from the Phase 3 INTerpath-001 study in August 2026, becoming the first personalized neoantigen therapy and mRNA cancer therapy to achieve success in a Phase 3 clinical study. Dr. Coder also co-invented and led development of the shared-antigen discovery and vaccine design framework for mRNA-4359 and mRNA-4106. He contributed to nine IND submissions as a co-inventor, research lead, or core contributor, and co-authored the Phase 1 KEYNOTE-603 study of mRNA-4157/V940 published in Cancer Discovery (2024). Prior to joining Moderna, Dr. Coder served as Associate Director of Immuno-Oncology Research at Advaxis Immunotherapies, where he developed personalized and off-the-shelf cancer vaccines. Leveraging its proprietary AI+mRNA platform, Everest Medicines is advancing multiple mRNA oncology therapeutic vaccine and in vivo CAR-T programs for oncology and autoimmune diseases. EVM16, a personalized mRNA therapeutic cancer vaccine, has completed its first-in-human clinical data readout, demonstrating a favorable safety and tolerability profile, robust immunogenicity and promising preliminary efficacy. Selected data were presented at the 2026 American Association for Cancer Research (AACR) Annual Meeting. Following the Phase 1a study, EVM16 plans to initiate an investigator-initiated trial (IIT) Phase 1b study in Q4 2026 and launch new indication expansion cohorts for efficacy exploration. The company plans to submit an IND application to the U.S. Food and Drug Administration (FDA) in the first half of 2027. EVM14, an off-the-shelf tumor-associated antigen (TAA) mRNA cancer vaccine, received IND clearance from the U.S. FDA and IND approval from China’s National Medical Products Administration (NMPA) in 2025. The Phase 1 monotherapy dose-escalation study is expected to be completed in Q1 2027.EVM18, an in vivo CAR-T therapy, has initiated an IIT study in autoimmune diseases, with global IND filing underway. EVM15, an off-the-shelf immunomodulatory (IM) cancer vaccine, achieved clinical proof of concept in preclinical studies in 2025, with a clinical candidate subsequently selected. The Company plans to advance preparations for the Investigational New Drug (IND) application for EVM15 in 2026.
- FDA approves Roche’s Tecentriq in combination with a fluoropyrimidine and oxaliplatin for the adjuvant treatment of a certain type of stage III colon cancerCompanies: Roche HoldingBasel, 9 October 2026 - Roche (SIX: RO, ROP; OTCQX: RHHBY) announced today that the US Food and Drug Administration (FDA) has approved Tecentriq® (atezolizumab) and Tecentriq Hybreza® (atezolizumab and hyaluronidase-tqjs) in combination with a fluoropyrimidine and oxaliplatin for the adjuvant treatment of stage III deficient DNA mismatch repair (dMMR) colon cancer, a type of tumour characterised by high mutation rates. This approval marks the twelfth indication for Tecentriq in the US.
- Akshayakalpa Organic expands High Protein portfolio with fresh new offeringsAkshayakalpa Organic, India’s leading certified organic dairy brand, has expanded its high-protein portfolio with the launch of High Protein Dahi, a protein-rich take on an everyday dairy staple, alongside High Protein Milk – Coffee and High Protein Milk – Kesar Elaichi. The new range brings together familiar dairy formats, taste and convenient nutrition to make […]
- SAP推動「自主營運企業」落地應用Companies: SAP香港, 2026年10月9日 - SAP在近日舉行的 SAP Connect 大會展示「自主營運企業」（Autonomous Enterprise）的實際應用，演示 Joule Work 與智能助手 Joule Assistants 如何為各業務範疇的客戶創造價值。 SAP 全球行政總裁柯睿安（Christian Klein） 表示：「這是企業級業務人工智能（Business AI）的突破性時刻，自主營運企業的應用正在加速落地。透過基於 SAP Business AI 平台構建的 Joule 及 SAP Autonomous Suite，我們正協助諾華（Novartis）、Morgan Foods、雀巢（Nestlé）及普華永道（PwC）等機構，在不同職能範疇推動智能化應用，並交付值得信賴的業務成果。」 在 SAP Connect 上，客戶們分享了Autonomous Enterprise正如何為其業務帶來可量